BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35024646)

  • 1. Safety of mass drug coadministration with ivermectin, diethylcarbamazine, albendazole, and azithromycin for the integrated treatment of neglected tropical diseases: a cluster randomized community trial.
    John LN; Gonzalez-Beiras C; Vall-Mayans M; Kolmau R; Houinei W; Wangi J; Marks M; Mitja O
    Lancet Reg Health West Pac; 2022 Jan; 18():100293. PubMed ID: 35024646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and safety study of co-administration of albendazole, diethylcarbamazine, Ivermectin and azithromycin for the integrated treatment of Neglected Tropical Diseases.
    John LN; Bjerum C; Martinez PM; Likia R; Silus L; Wali C; Elizah A; Chhonker YS; Bala V; King CL; Murry DJ; Mitja O; Marks M
    Clin Infect Dis; 2020 Aug; ():. PubMed ID: 32818264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia.
    McPherson S; Tafese G; Tafese T; Behaksra SW; Solomon H; Oljira B; Miecha H; Debebe KA; Kebede B; Gebre T; Kebede F; Seife F; Tadesse F; Mammo B; Aseffa A; Solomon AW; Mabey DCW; Marks M; Gadisa E
    EClinicalMedicine; 2023 May; 59():101984. PubMed ID: 37152362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
    Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
    PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial.
    Romani L; Marks M; Sokana O; Nasi T; Kamoriki B; Wand H; Whitfeld MJ; Engelman D; Solomon AW; Steer AC; Kaldor JM
    Lancet Glob Health; 2018 Oct; 6(10):e1132-e1138. PubMed ID: 30223985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
    Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008106. PubMed ID: 32176703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali.
    Coulibaly YI; Dicko I; Keita M; Keita MM; Doumbia M; Daou A; Haidara FC; Sankare MH; Horton J; Whately-Smith C; Sow SO
    PLoS Negl Trop Dis; 2013; 7(5):e2221. PubMed ID: 23675549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study.
    Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
    Drug Saf; 2023 Oct; 46(10):961-974. PubMed ID: 37552438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, feasibility and safety of co-administering azithromycin, albendazole, and ivermectin during mass drug administration: A review.
    McPherson S; Solomon AW; Seife F; Solomon H; Gebre T; Mabey DCW; Marks M
    PLoS Negl Trop Dis; 2023 Jun; 17(6):e0011224. PubMed ID: 37315102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d'Ivoire: An Open-label Randomized Controlled Trial.
    Bjerum CM; Ouattara AF; Aboulaye M; Kouadio O; Marius VK; Andersen BJ; Weil GJ; Koudou BG; King CL
    Clin Infect Dis; 2020 Oct; 71(7):e68-e75. PubMed ID: 31641754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
    Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial.
    Romani L; Marks M; Sokana O; Nasi T; Kamoriki B; Cordell B; Wand H; Whitfeld MJ; Engelman D; Solomon AW; Kaldor JM; Steer AC
    Lancet Infect Dis; 2019 May; 19(5):510-518. PubMed ID: 30956111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study.
    Fimbo AM; Minzi OM; Mmbando BP; Gurumurthy P; Kamuhabwa AAR; Aklillu E
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial.
    Mitjà O; Hays R; Ipai A; Penias M; Paru R; Fagaho D; de Lazzari E; Bassat Q
    Lancet; 2012 Jan; 379(9813):342-7. PubMed ID: 22240407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
    Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
    Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.